WO2012173581A1 - Thiocolchicoside, etodolac and famotidine combinations - Google Patents
Thiocolchicoside, etodolac and famotidine combinations Download PDFInfo
- Publication number
- WO2012173581A1 WO2012173581A1 PCT/TR2012/000053 TR2012000053W WO2012173581A1 WO 2012173581 A1 WO2012173581 A1 WO 2012173581A1 TR 2012000053 W TR2012000053 W TR 2012000053W WO 2012173581 A1 WO2012173581 A1 WO 2012173581A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- composition comprises
- famotidine
- etodolac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Definitions
- the present invention relates to the pharmaceutical compositions in unit dosage form comprising thiocolchicoside as a muscle relaxant, etodolac as a non-steroidal antiinflammatory drug and famotidine as a gastroprotectant; and to the preparation methods thereof.
- Pharmaceutical compositions of the invention are used in the treatment of muscular and skeletal system diseases as well as inflammation and pain; and are safe due to the reduced gastrointestinal side effects. Background of the invention
- the present invention relates to the unit dosage forms comprising
- NSAID non-steroidal anti-inflammatory drug
- Unit dosage forms of the invention comprises
- thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as a muscle relaxant
- Unit dosage forms of the invention comprise thiocolchicoside as a muscle relaxant in an amount of from 4 to 16 mg, preferably in an amount of 8 mg; etodolac as an NSAID in an amount of from 200 to 1200 mg, preferably in an amount of 400 mg; and famotidine as a gastroprotectant in an amount of from 5 to 200 mg, preferably in an amount of 20 mg.
- Pharmaceutical combinations of the invention used in the treatment of muscular and skeletal system diseases as well as inflammation and pain can reduce the gastrointestinal side effects induced by the NSAID content in the composition due to the presence of the gastroprotectant in said composition.
- Thiocolchicoside is a glycosulfurated analogue of colchicine and is a well known centrally acting muscle relaxant used in the treatment of muscular and skeletal system diseases. Its chemical structure is shown in Formula 1.
- thiocolchicoside N-[3-(P-D-glucopyranosyloxy)-l,2-dimethoxy-10- (methylthio)-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide.
- the usual initial dose is 16 mg daily by oral administration in the form of capsule or tablet. It is also used for intramuscular administration in doses up to 8 mg per day or for topical application as cream, ointment, gel or aerosol.
- Etodolac is an NSAID used in the treatment of inflammation and pain. It possesses analgesic and antipyretic properties as well as anti-inflammatory activity. Its chemical structure is shown in Formula 2.
- etodolac is l,8-diethyl-l,3,4,9-tetrahydropyrano (3,4-b) indol-l-yl acetic acid.
- Famotidine is an H2-reseptor antagonist used in the treatment of gastrointestinal diseases. It protects the gastric mucosa against irritation. Its chemical structure is shown in Formula 3.
- famotidine 3-(2-(diaminomethyleneamino)thiazol-4-yl methylthio)- N-sulfamoyl propionamidine.
- the usual initial dose is 40 mg daily by oral administration in the form of tablet or intravenous administration.
- Centrally acting skeletal muscle relaxants are generally prescribed either as single agents or as components of combination products.
- Several commercial combinations of a muscle relaxant and aspirin (carisoprodol + aspirin, carisoprodol + aspirin + codeine, methocarbamol + aspirin and orphenadrine + aspirin + caffeine) have been approved by the U.S. Food and Drug Administration (U.S. FDA) and are marketed in the USA.
- NSAIDs can cause gastrointestinal ulseration, bleeding and perforation; especially in case of high dose usage, long-term treatments, history of a gastrointestinal disease or sensitivity to develop disease; additional use of gastroprotectant drugs for reducing gastrointestinal irritation is needed.
- the present invention is directed to the pharmaceutical compositions in unit dosage form wherein the patient compliance is increased, the composition is used for the treatment of muscular and skeletal system diseases as well as inflammation and pain, and gastrointestinal side effects are reduced.
- compositions of the invention comprise thiocolchicoside as muscle relaxant, etodolac as NSAID and famotidine as gastroprotectant in a single dosage form.
- French patent FR 2725134 Bl (Laboratoire Lederle) relates to a new combination comprising ibuprofen or a pharmaceutically acceptable salt thereof and thiocolchicoside or a pharmaceutically acceptable salt thereof in a weight ratio of between about 1 :50 and about 1 :200 for oral administration in the form of a capsule, tablet or granule.
- European patent EP 0837684 Bl (Sanofi-Synthelabo) relates to a new combination comprising a diclofenac salt and thiocolchicoside with at least one pharmaceutically acceptable excipient, wherein said combination is in solid form which is stable over time.
- European patent application EP 1992333 Al (Sanovel) relates to a combination comprising flurbiprofen and an alpha-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist, particularly tizanidine and thiocolchicoside.
- European patent EP 141 1900 Bl relates to a multi-layer tablet suitable for oral administration comprising an outer layer of an acid inhibitor (H2-receptor antagonist, preferably famotidine, or proton pump inhibitor), an inner core of an NSAID (preferably aspirin or naproxen) and a barrier coating surrounding the inner core of said NSAID.
- H2-receptor antagonist preferably famotidine, or proton pump inhibitor
- NSAID preferably aspirin or naproxen
- NSAID preferably naproxen or ibuprofen
- acid blocking agent preferably ranitidine
- NSAIDs preferably aspirin, naproxen, diclofenac or ibuprofen
- gastroprotectants preferably famotidine, proton pump inhibitors, misoprostol or ranitidine.
- said patents do not clearly include even the binary combinations of etodolac and famotidine which are comprised in the triple combinations of the invention.
- the present invention discloses novel and stable unit dosage forms comprising thiocolchicoside as muscle relaxant, etodolac as NSAID and famotidine as gastroprotectant.
- the present invention relates to a pharmaceutical composition for use in the treatment of muscular and skeletal system diseases, inflammation and pain in mammalian organism and adapted for unit administration, wherein the pharmaceutical composition comprises
- thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as muscle relaxant b) etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as NSAID; c) famotidine or a pharmaceutically acceptable salt thereof as gastroprotectant; and
- the present invention encompasses unit dosage forms comprising a muscle relaxant, a nonsteroidal anti-inflammatory drug (NSAID) and a gastroprotectant.
- NSAID nonsteroidal anti-inflammatory drug
- the muscle relaxant of the invention is preferably thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof.
- the NSAID of the invention may preferably be selected from an acetic acid derivative, a propionic acid derivative, an enolic acid derivative, a fenamic acid derivative, a COX-2 inhibitor, a salicylate and other NSAI drugs.
- the acetic acid derivative of the invention may be selected from, but is not limited to, etodolac, ketorolac, diclofenac, indomethacin, sulindac and nabumeton; and is preferably etodolac.
- Etodolac may be in the form of a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof.
- the propionic acid derivative of the invention may be selected from, but is not limited to, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and loxoprofen.
- the enolic acid derivative of the invention may be selected from, but is not limited to, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam.
- the fenamic acid derivative of the invention may be selected from, but is not limited to, mefenamic acid, meclofenamic acid, flufenamic acid and tolfenamic acid.
- the COX-2 inhibitor of the invention may be selected from, but is not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib and etoricoxib.
- the salicylate of the invention may be selected from, but is not limited to, acetylsalicylic acid, salsalate and diflunisal.
- the other NSAI drugs of the invention may be selected from, but are not limited to, nimesulide and licofelone.
- the gastroprotectant of the invention may preferably be selected from an H2-receptor antagonist, a proton pump inhibitor, an antiacid or a prostaglandin.
- the H2-receptor antagonist of the invention may be selected from, but is not limited to, famotidine, cimetidine, ranitidine, ebrotidine, pabutidine, lafutidine, loxtidine, nizatidine, roxatidine, tiotidine, niperotidine and oxmetidine; and is preferably famotidine. Famotidine may be in free form or in the form of a pharmaceutically acceptable salt thereof.
- the proton pump inhibitor of the invention may be selected from, but is not limited to, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole and leminoprazole.
- the antiacid of the invention may be selected from, but is not limited to, CaC0 3 , MgC0 3 , Mg(OH) 2 , Al(OH) 3 , NaHC0 3 and KHC0 3 .
- the prostaglandin of the invention may be selected from, but is not limited to, misoprostol and enprostil.
- the present invention relates to a combination of thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as muscle relaxant; etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as NSAID; famotidine or a pharmaceutically acceptable salt thereof as gastroprotectant and at least one pharmaceutically acceptable nontoxic carrier, wherein said combination is developed for unit dose application.
- Combinations of the invention comprise thiocolchicoside as a muscle relaxant in an amount of from 4 to 16 mg, preferably in an amount of 8 mg; etodolac as an NSAID in an amount of from 200 to 1200 mg, preferably in an amount of 400 mg; and famotidine as a gastroprotectant in an amount of from 5 to 200 mg, preferably in an amount of 20 mg.
- thiocolchicoside to a standard NSAID treatment has shown more effective results for the treatment of muscular and skeletal system diseases as well as inflammation and pain than NSAID treatment alone.
- Combinations of the invention may be used for oral, buccal, ocular, otic, rectal, topical, implantal, mucosal, parenteral, sublingal, nasal or pulmonary administration in the form of gel, cream, ointment, tablet, capsule, drop, pellet, granule, solution, suspension, syrup, powder, injectable suspension, injectable powder and injectable solution; and are preferably in oral dosage form; more preferably in tablet form.
- Dosage forms of the invention may be administered once or twice a day.
- Therapeutically effective amount of thiocolchicoside included in the dosage forms of the invention is between 4 mg and 16 mg, preferably 8 mg.
- Therapeutically effective amount of etodolac included in the dosage forms of the invention is between 200 mg and 1200 mg, preferably 400 mg.
- Therapeutically effective amount of famotidine included in the dosage forms of the invention is between 5 mg and 200 mg, preferably 20 mg.
- Oral dosage forms of the invention preferably in tablet form may comprise a pharmaceutically acceptable non-toxic inert carrier such as lactose, microcrystalline cellulose, starch, pre- gelatinized starch, calcium phosphate, calcium sulfate, calcium carbonate, mannitol, sorbitol, xylitol, sucrose, maltose, fructose, dextrose and the like.
- Oral dosage forms of the invention may optionally comprise suitable binders, lubricants, disintegrating agents, flavoring agents, sweetening agents, coloring agents and coating agents.
- Suitable binders of the invention may be selected from starches, natural sugars, corn sweeteners, natural and synthetic gums, cellulose derivatives, gelatin, PVP, polyethylene glycols, waxes, sodium alginate, alcohols, water and the like.
- Suitable lubricants of the invention may be selected from metallic stearates, metallic lauryl sulfates, fatty acids, fatty acid esters, fatty alcohols, paraffins, hydrogenated vegetable oils, polyethylene glycols, boric acid, sodium benzoate, sodium acetate, sodium chloride, talk and the like.
- Suitable disintegrating agents of the invention may be selected from starches, cellulose derivatives, PVP, crospovidone, clays, ion-exchange resins, alginic acid, sodium alginate and the like.
- Suitable coating agents of the invention may be selected from hydroxypropylmethylcellulose as a film coating agent, PEG 400 as a plasticizer, titanium dioxide and iron oxide as coloring agents.
- the present invention may comprise an injectable unit dosage form for intravenous, intramuscular or subcutaneous administration formulated as aqueous or non-aqueous solution or suspension, or as powder for injection, with suitable pharmaceutically acceptable non-toxic excipients.
- the present invention may also comprise extended, modified or controlled release (controlled, prolonged, sustained, immediate, timed, slow or fast release) tablet or capsule to provide the control of the release of the active components, preferably thiocolchicoside and/or etodolac and/or famotidine in order to optimize the therapeutic effects and minimize the undesirable side effects.
- extended, modified or controlled release controlled, prolonged, sustained, immediate, timed, slow or fast release
- compositions of the inventions are used in the treatment of muscular and skeletal system diseases as well as inflammation and pain; and have reduced gastrointestinal side effects.
- Pharmaceutical compositions of the inventions may be administered once or twice a day in unit doses.
- compositions of the inventions Table 1 : Film tablet
- PVP PVP
- Etodolac remaining amount of PVP (K-30), lactose, microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide are mixed together.
- the obtained mixture is wet-granulated with the PVP (K-30) solution. Granules so-obtained are dried and pass through the dry granulator.
- thiocolchicoside and famotidine are added to the granules obtained in the first stage. Suitable mixing is applied. Final mixture is obtained by the addition of magnesium stearate to the mixture. After the tablets are pressed, they are film-coated. 2. Preparation method wherein the active components are directly mixed
- PVP (K-30) A certain amount of PVP (K-30) is dissolved in purified water. Etodolac, thiocolchicoside, famotidine, remaining amount of PVP (K-30), lactose, microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide are mixed together. The obtained mixture is wet- granulated with the PVP (K-30) solution. Granules so-obtained are dried and pass through the dry granulator. Final mixture is obtained by the addition of magnesium stearate to the mixture. After the tablets are pressed, they are film-coated.
- Tablets prepared by the processes of the invention have not met any stability problems during long term stability studies performed at 25 ⁇ 2 °C and 60 ⁇ 5 % RH across a 0-, 3- and 6- month follow-up period; and accelerated stability studies performed at 40 ⁇ 2 °C and 75 ⁇ 5 % RH across a 0-, 3- and 6-month follow-up period.
Abstract
The present invention relates to the unit dosage forms comprising a. thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as a muscle relaxant, b. etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as an NSAID, and c. famotidine or a pharmaceutically acceptable salt thereof as a gastroprotectant.
Description
DESCRIPTION
THIOCOLCHICOSIDE, ETODOLAC AND FAMOTIDINE COMBINATIONS Field of the invention
The present invention relates to the pharmaceutical compositions in unit dosage form comprising thiocolchicoside as a muscle relaxant, etodolac as a non-steroidal antiinflammatory drug and famotidine as a gastroprotectant; and to the preparation methods thereof. Pharmaceutical compositions of the invention are used in the treatment of muscular and skeletal system diseases as well as inflammation and pain; and are safe due to the reduced gastrointestinal side effects. Background of the invention
The present invention relates to the unit dosage forms comprising
a. a muscle relaxant,
b. a non-steroidal anti-inflammatory drug (an NSAID), and
c. a gastroprotectant. Unit dosage forms of the invention comprises
a. thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as a muscle relaxant,
b. etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as an NSAID, and
c. famotidine or a pharmaceutically acceptable salt thereof as a gastroprotectant:
Unit dosage forms of the invention comprise thiocolchicoside as a muscle relaxant in an amount of from 4 to 16 mg, preferably in an amount of 8 mg; etodolac as an NSAID in an amount of from 200 to 1200 mg, preferably in an amount of 400 mg; and famotidine as a gastroprotectant in an amount of from 5 to 200 mg, preferably in an amount of 20 mg. Pharmaceutical combinations of the invention used in the treatment of muscular and skeletal system diseases as well as inflammation and pain can reduce the gastrointestinal side effects induced by the NSAID content in the composition due to the presence of the gastroprotectant in said composition.
Thiocolchicoside is a glycosulfurated analogue of colchicine and is a well known centrally acting muscle relaxant used in the treatment of muscular and skeletal system diseases. Its chemical structure is shown in Formula 1.
Formula 1
The chemical name of thiocolchicoside is N-[3-(P-D-glucopyranosyloxy)-l,2-dimethoxy-10- (methylthio)-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide.
The usual initial dose is 16 mg daily by oral administration in the form of capsule or tablet. It is also used for intramuscular administration in doses up to 8 mg per day or for topical application as cream, ointment, gel or aerosol.
Etodolac is an NSAID used in the treatment of inflammation and pain. It possesses analgesic and antipyretic properties as well as anti-inflammatory activity. Its chemical structure is shown in Formula 2.
Formula 2
The chemical name of etodolac is l,8-diethyl-l,3,4,9-tetrahydropyrano (3,4-b) indol-l-yl acetic acid.
The usual initial dose is 200-400 mg daily for acute pain, 800-1200 mg daily for inflammation-related diseases by oral administration in the form of tablet.
Famotidine is an H2-reseptor antagonist used in the treatment of gastrointestinal diseases. It protects the gastric mucosa against irritation. Its chemical structure is shown in Formula 3.
Formula 3 The chemical name of famotidine is 3-(2-(diaminomethyleneamino)thiazol-4-yl methylthio)- N-sulfamoyl propionamidine.
The usual initial dose is 40 mg daily by oral administration in the form of tablet or intravenous administration.
Centrally acting skeletal muscle relaxants are generally prescribed either as single agents or as components of combination products. Several commercial combinations of a muscle relaxant and aspirin (carisoprodol + aspirin, carisoprodol + aspirin + codeine, methocarbamol + aspirin and orphenadrine + aspirin + caffeine) have been approved by the U.S. Food and Drug Administration (U.S. FDA) and are marketed in the USA.
Due to the fact that NSAIDs can cause gastrointestinal ulseration, bleeding and perforation; especially in case of high dose usage, long-term treatments, history of a gastrointestinal disease or sensitivity to develop disease; additional use of gastroprotectant drugs for reducing gastrointestinal irritation is needed.
In cases where use of more than one medicine is needed, patient compliance is an important factor to be considered. According to the research, 50% of the patients fail to take medicines as prescribed and to fulfill the requirements of the treatment (Sabate, E. "Adherence to Long- Term Therapies: Evidence for Action". World Health Organization. Geneva, 2003. 212 pp.). Patients fail to take their medicines prescribed so as to include a complicated treatment regimen requiring use of more than one medicine due to the facts such as forgetfulness, busy lifestyle, different methods of the administration of the medicines, lack of suitable environment for taking medicines, misunderstanding of the disease or treatment, patient's perspective of the disease or treatment, side effects, depression, cognitive disorders and
financial problems. In this case, combining the active components in a single dosage form will increase patient compliance to the treatment.
The present invention is directed to the pharmaceutical compositions in unit dosage form wherein the patient compliance is increased, the composition is used for the treatment of muscular and skeletal system diseases as well as inflammation and pain, and gastrointestinal side effects are reduced.
Pharmaceutical compositions of the invention comprise thiocolchicoside as muscle relaxant, etodolac as NSAID and famotidine as gastroprotectant in a single dosage form.
Binary combinations of thiocolchicoside as muscle relaxant and NSAIDs as well as NSAIDs and gastroprotectants have been disclosed in the prior art. But, any information relating to the combinations of the invention comprising all active components (thiocolchicoside, etodolac and famotidine) combined in unit dosage form has not been disclosed.
French patent FR 2725134 Bl (Laboratoire Lederle) relates to a new combination comprising ibuprofen or a pharmaceutically acceptable salt thereof and thiocolchicoside or a pharmaceutically acceptable salt thereof in a weight ratio of between about 1 :50 and about 1 :200 for oral administration in the form of a capsule, tablet or granule.
European patent EP 0837684 Bl (Sanofi-Synthelabo) relates to a new combination comprising a diclofenac salt and thiocolchicoside with at least one pharmaceutically acceptable excipient, wherein said combination is in solid form which is stable over time. European patent application EP 1992333 Al (Sanovel) relates to a combination comprising flurbiprofen and an alpha-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist, particularly tizanidine and thiocolchicoside.
International patent application WO2010084500 Al (Sanofi-Synthelabo) relates to a combination in the form of a solid dosage form containing ketoprofen and thiocolchicoside, wherein the active ingredients are present in the free form or in the form of a salt and not being intimately mixed in the composition.
Above-mentioned patents relate to the combined use of thiocolchicoside and specific NSAIDs (ibuprofen, diclofenac, flurbiprofen and ketoprofen, respectively). But, said patents do not
include even the binary combinations of etodolac and thiocolchicoside which are comprised in the triple combinations of the invention.
European patent EP 141 1900 Bl (Pozen) relates to a multi-layer tablet suitable for oral administration comprising an outer layer of an acid inhibitor (H2-receptor antagonist, preferably famotidine, or proton pump inhibitor), an inner core of an NSAID (preferably aspirin or naproxen) and a barrier coating surrounding the inner core of said NSAID.
American patent application US 20070237820 Al (Andrx) relates to a solid oral dosage form comprising a first portion comprising an NSAID (preferably diclofenac); and a coating comprising an antiulcerative compound (preferably misoprostol); said coating at least partially surrounding said first NSAID portion.
American patent application US 20090233970 Al relates to a pharmaceutical composition for the treatment of pain and inflammation with reduced gastrointestinal irritation, the composition comprising at least one NSAID (preferably naproxen or ibuprofen); and at least one acid blocking agent (preferably ranitidine). Above-mentioned patents relate to the combined use of NSAIDs (preferably aspirin, naproxen, diclofenac or ibuprofen) and gastroprotectants (preferably famotidine, proton pump inhibitors, misoprostol or ranitidine). But, said patents do not clearly include even the binary combinations of etodolac and famotidine which are comprised in the triple combinations of the invention. As a result, the present invention discloses novel and stable unit dosage forms comprising thiocolchicoside as muscle relaxant, etodolac as NSAID and famotidine as gastroprotectant.
Summary of the invention
The present invention relates to a pharmaceutical composition for use in the treatment of muscular and skeletal system diseases, inflammation and pain in mammalian organism and adapted for unit administration, wherein the pharmaceutical composition comprises
a) thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as muscle relaxant; b) etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as NSAID;
c) famotidine or a pharmaceutically acceptable salt thereof as gastroprotectant; and
d) at least one pharmaceutically acceptable non-toxic carrier.
Detailed description of the invention The present invention encompasses unit dosage forms comprising a muscle relaxant, a nonsteroidal anti-inflammatory drug (NSAID) and a gastroprotectant.
The muscle relaxant of the invention is preferably thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof.
The NSAID of the invention may preferably be selected from an acetic acid derivative, a propionic acid derivative, an enolic acid derivative, a fenamic acid derivative, a COX-2 inhibitor, a salicylate and other NSAI drugs.
The acetic acid derivative of the invention may be selected from, but is not limited to, etodolac, ketorolac, diclofenac, indomethacin, sulindac and nabumeton; and is preferably etodolac. Etodolac may be in the form of a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof.
The propionic acid derivative of the invention may be selected from, but is not limited to, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and loxoprofen.
The enolic acid derivative of the invention may be selected from, but is not limited to, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam. The fenamic acid derivative of the invention may be selected from, but is not limited to, mefenamic acid, meclofenamic acid, flufenamic acid and tolfenamic acid.
The COX-2 inhibitor of the invention may be selected from, but is not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib and etoricoxib.
The salicylate of the invention may be selected from, but is not limited to, acetylsalicylic acid, salsalate and diflunisal.
The other NSAI drugs of the invention may be selected from, but are not limited to, nimesulide and licofelone.
The gastroprotectant of the invention may preferably be selected from an H2-receptor antagonist, a proton pump inhibitor, an antiacid or a prostaglandin. The H2-receptor antagonist of the invention may be selected from, but is not limited to, famotidine, cimetidine, ranitidine, ebrotidine, pabutidine, lafutidine, loxtidine, nizatidine, roxatidine, tiotidine, niperotidine and oxmetidine; and is preferably famotidine. Famotidine may be in free form or in the form of a pharmaceutically acceptable salt thereof.
The proton pump inhibitor of the invention may be selected from, but is not limited to, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole and leminoprazole.
The antiacid of the invention may be selected from, but is not limited to, CaC03, MgC03, Mg(OH)2, Al(OH)3, NaHC03 and KHC03.
The prostaglandin of the invention may be selected from, but is not limited to, misoprostol and enprostil.
The present invention relates to a combination of thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as muscle relaxant; etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as NSAID; famotidine or a pharmaceutically acceptable salt thereof as gastroprotectant and at least one pharmaceutically acceptable nontoxic carrier, wherein said combination is developed for unit dose application.
Combinations of the invention comprise thiocolchicoside as a muscle relaxant in an amount of from 4 to 16 mg, preferably in an amount of 8 mg; etodolac as an NSAID in an amount of from 200 to 1200 mg, preferably in an amount of 400 mg; and famotidine as a gastroprotectant in an amount of from 5 to 200 mg, preferably in an amount of 20 mg.
The addition of thiocolchicoside to a standard NSAID treatment has shown more effective results for the treatment of muscular and skeletal system diseases as well as inflammation and
pain than NSAID treatment alone. The addition of a gastroprotectant to said combination has substantially reduced the gastrointestinal side effects of the NSAID.
Combinations of the invention may be used for oral, buccal, ocular, otic, rectal, topical, implantal, mucosal, parenteral, sublingal, nasal or pulmonary administration in the form of gel, cream, ointment, tablet, capsule, drop, pellet, granule, solution, suspension, syrup, powder, injectable suspension, injectable powder and injectable solution; and are preferably in oral dosage form; more preferably in tablet form. Dosage forms of the invention may be administered once or twice a day. Therapeutically effective amount of thiocolchicoside included in the dosage forms of the invention is between 4 mg and 16 mg, preferably 8 mg. Therapeutically effective amount of etodolac included in the dosage forms of the invention is between 200 mg and 1200 mg, preferably 400 mg. Therapeutically effective amount of famotidine included in the dosage forms of the invention is between 5 mg and 200 mg, preferably 20 mg.
Oral dosage forms of the invention preferably in tablet form may comprise a pharmaceutically acceptable non-toxic inert carrier such as lactose, microcrystalline cellulose, starch, pre- gelatinized starch, calcium phosphate, calcium sulfate, calcium carbonate, mannitol, sorbitol, xylitol, sucrose, maltose, fructose, dextrose and the like. Oral dosage forms of the invention may optionally comprise suitable binders, lubricants, disintegrating agents, flavoring agents, sweetening agents, coloring agents and coating agents. Suitable binders of the invention may be selected from starches, natural sugars, corn sweeteners, natural and synthetic gums, cellulose derivatives, gelatin, PVP, polyethylene glycols, waxes, sodium alginate, alcohols, water and the like. Suitable lubricants of the invention may be selected from metallic stearates, metallic lauryl sulfates, fatty acids, fatty acid esters, fatty alcohols, paraffins, hydrogenated vegetable oils, polyethylene glycols, boric acid, sodium benzoate, sodium acetate, sodium chloride, talk and the like. Suitable disintegrating agents of the invention may be selected from starches, cellulose derivatives, PVP, crospovidone, clays, ion-exchange resins, alginic acid, sodium alginate and the like. Suitable coating agents of the invention may be selected from hydroxypropylmethylcellulose as a film coating agent, PEG 400 as a plasticizer, titanium dioxide and iron oxide as coloring agents. The present invention may comprise an injectable unit dosage form for intravenous, intramuscular or subcutaneous administration formulated as aqueous or non-aqueous solution
or suspension, or as powder for injection, with suitable pharmaceutically acceptable non-toxic excipients.
The present invention may also comprise extended, modified or controlled release (controlled, prolonged, sustained, immediate, timed, slow or fast release) tablet or capsule to provide the control of the release of the active components, preferably thiocolchicoside and/or etodolac and/or famotidine in order to optimize the therapeutic effects and minimize the undesirable side effects.
Pharmaceutical compositions of the inventions are used in the treatment of muscular and skeletal system diseases as well as inflammation and pain; and have reduced gastrointestinal side effects. Pharmaceutical compositions of the inventions may be administered once or twice a day in unit doses.
Examples
Pharmaceutical compositions of the inventions Table 1 : Film tablet
1. Preparation method wherein the active components are not directly mixed
At the first stage, a certain amount of PVP (K-30) is dissolved in purified water. Etodolac, remaining amount of PVP (K-30), lactose, microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide are mixed together. The obtained mixture is wet-granulated with the PVP (K-30) solution. Granules so-obtained are dried and pass through the dry granulator.
At the second stage, thiocolchicoside and famotidine are added to the granules obtained in the first stage. Suitable mixing is applied. Final mixture is obtained by the addition of magnesium stearate to the mixture. After the tablets are pressed, they are film-coated. 2. Preparation method wherein the active components are directly mixed
A certain amount of PVP (K-30) is dissolved in purified water. Etodolac, thiocolchicoside, famotidine, remaining amount of PVP (K-30), lactose, microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide are mixed together. The obtained mixture is wet- granulated with the PVP (K-30) solution. Granules so-obtained are dried and pass through the dry granulator. Final mixture is obtained by the addition of magnesium stearate to the mixture. After the tablets are pressed, they are film-coated.
Tablets prepared by the processes of the invention have not met any stability problems during long term stability studies performed at 25 ± 2 °C and 60 ± 5 % RH across a 0-, 3- and 6- month follow-up period; and accelerated stability studies performed at 40 ± 2 °C and 75 ± 5 % RH across a 0-, 3- and 6-month follow-up period.
The extent of the invention should not be limited by the examples. The examples above are only given to illustrate the invention.
Claims
1. A pharmaceutical composition for use in the treatment of muscular and skeletal system diseases, inflammation and pain in mammalian organism and adapted for unit administration, wherein the pharmaceutical composition comprises
a) a muscle relaxant;
b) an NSAID;
c) a gastroprotectant; and
d) at least one pharmaceutically acceptable non-toxic carrier.
2. Pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as muscle relaxant.
3. Pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises a drug selected from an acetic acid derivative, a propionic acid derivative, an enolic acid derivative, a fenamic acid derivative, a COX-2 inhibitor, a salicylate and other NSAI drugs as NSAID.
4. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from etodolac, ketorolac, diclofenac, indomethacin, sulindac and nabumeton as acetic acid derivative.
5. Pharmaceutical composition according to claim 4, wherein the pharmaceutical composition comprises etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as acetic acid derivative.
6. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and loxoprofen as propionic acid derivative.
7. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam as enolic acid derivative.
8. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from mefenamic acid, meclofenamic acid, flufenamic acid and tolfenamic acid as fenamic acid derivative.
9. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib and etoricoxib as COX-2 inhibitor.
10. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from acetylsalicylic acid, salsalate and diflunisal as salicylate.
1 1. Pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises a drug selected from nimesulide and licofelone as other NSAI drugs.
12. Pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises a drug selected from an H2-receptor antagonist, a proton pump inhibitor, an antiacid or a prostaglandin as gastroprotectant.
13. Pharmaceutical composition according to claim 12, wherein the pharmaceutical composition comprises a drug selected from famotidine, cimetidine, ranitidine, ebrotidine, pabutidine, lafutidine, loxtidine, nizatidine, roxatidine, tiotidine, niperotidine and oxmetidine as H2-receptor antagonist.
14. Pharmaceutical composition according to claim 13, wherein the pharmaceutical composition comprises famotidine or a pharmaceutically acceptable salt thereof as
H2 -receptor antagonist.
15. Pharmaceutical composition according to claim 12, wherein the pharmaceutical composition comprises a drug selected from omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole and leminoprazole as proton pump inhibitor.
16. Pharmaceutical composition according to claim 12, wherein the pharmaceutical composition comprises a drug selected from CaC03, MgC03, Mg(OH)2, Al(OH)3, NaHC03 and KHC03 as antiacid.
17. Pharmaceutical composition according to claim 12, wherein the pharmaceutical composition comprises a drug selected from misoprostol and enprostil as prostaglandin.
18. A pharmaceutical composition for use in the treatment of muscular and skeletal system diseases, inflammation and pain in mammalian organism and adapted for unit administration, wherein the pharmaceutical composition comprises
a) thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as muscle relaxant; b) etodolac or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as NSAID; c) famotidine or a pharmaceutically acceptable salt thereof as gastroprotectant; and
d) at least one pharmaceutically acceptable non-toxic carrier.
19. Pharmaceutical composition according to claim 1 or 18, wherein the pharmaceutical composition comprises thiocolchicoside in an amount of from 4 to 16 mg, etodolac in an amount of from 200 to 1200 mg and famotidine in an amount of from 5 to 200 mg.
20. Pharmaceutical composition according to claim 1 or 18, wherein the pharmaceutical composition comprises thiocolchicoside in an amount of 8 mg, etodolac in an amount of 400 mg and famotidine in an amount of 20 mg.
21. Pharmaceutical composition according to claim 1 or 18, wherein the pharmaceutical composition is adapted for oral, buccal, ocular, otic, rectal, topical, implantal, mucosal, parenteral, sublingal, nasal and pulmonary administration of the pharmaceutical dosage form.
22. Pharmaceutical composition according to claim 21, wherein the pharmaceutical composition is adapted for oral administration of the pharmaceutical dosage form.
23. Pharmaceutical composition according to claim 1 or 18, wherein the pharmaceutical composition is adapted to be in the form of gel, cream, ointment, tablet, capsule, drop, pellet, granule, solution, suspension, syrup, powder, injectable suspension, injectable powder and injectable solution.
24. Pharmaceutical composition according to claim 23, wherein the pharmaceutical composition is adapted to be in the form of tablet.
25. Pharmaceutical composition according to claim 1 or 18, wherein the pharmaceutical composition is adapted to provide controlled, prolonged, sustained, immediate, timed, slow and fast release of the active components.
26. Pharmaceutical composition according to claim 1 or 18, wherein the pharmaceutical composition is adapted to be administered once and twice a day in unit doses.
27. Preparation process of the pharmaceutical composition according to claim 1 or 18, wherein the process comprises the steps of
- at the first stage, dissolving a certain amount of PVP (K-30) in purified water; mixing etodolac, remaining amount of PVP (K-30), lactose, microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide together; wet- granulating the obtained mixture with the PVP (K-30) solution; drying the granules so-obtained and passing the granules through the dry granulator; and - at the second stage, adding thiocolchicoside and famotidine to the granules obtained in the first stage; applying suitable mixing; obtaining final mixture by the addition of magnesium stearate to the mixture; pressing and film-coating the tablets.
28. Preparation process of the pharmaceutical composition according to claim 1 or 18, wherein the process comprises the steps of dissolving a certain amount of PVP (K-30) in purified water; mixing etodolac, thiocolchicoside, famotidine, remaining amount of PVP (K-30), lactose, microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide together; wet-granulating the obtained mixture with the PVP (K-30) solution; drying the granules so-obtained and passing the granules through the dry granulator; obtaining final mixture by the addition of magnesium stearate to the mixture; pressing and film-coating the tablets.
29. Use of a pharmaceutical composition according to any one of the preceding claims in the treatment of muscular and skeletal system diseases, inflammation and pain in mammalian organism.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201102628 | 2011-03-21 | ||
| TR2011/02628 | 2011-03-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012173581A1 true WO2012173581A1 (en) | 2012-12-20 |
| WO2012173581A4 WO2012173581A4 (en) | 2013-03-14 |
Family
ID=46889408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2012/000053 WO2012173581A1 (en) | 2011-03-21 | 2012-03-21 | Thiocolchicoside, etodolac and famotidine combinations |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012173581A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015163832A1 (en) | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
| WO2016001133A1 (en) * | 2014-06-30 | 2016-01-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and gamma-aminobutiric acid receptor agonist combinations |
| WO2016046189A1 (en) * | 2014-09-24 | 2016-03-31 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and antispastic drug combinations |
| WO2018004498A1 (en) * | 2016-06-30 | 2018-01-04 | Imuneks Farma Ilac San. Ve Tic. A.S. | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation |
| WO2019098983A1 (en) * | 2017-11-16 | 2019-05-23 | Pisak Mehmet Nevzat | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation |
| WO2019135725A1 (en) * | 2018-01-03 | 2019-07-11 | Pisak Mehmet Nevzat | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation |
| WO2020018048A3 (en) * | 2018-05-28 | 2020-07-16 | Pisak Mehmet Nevzat | An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate |
| CN114699380A (en) * | 2021-12-27 | 2022-07-05 | 南京联智医药科技有限公司 | Etodolac tablet and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725134A1 (en) * | 1994-10-04 | 1996-04-05 | Lederle Lab | Pharmaceutical compsn. of ibuprofen and thiocolchicoside |
| FR2735369A1 (en) * | 1995-06-13 | 1996-12-20 | Synthelabo | PHARMACEUTICAL COMPOSITIONS BASED ON SODIUM SALT OF DICLOFENAC AND THIOCOLCHICOSIDE |
| US20050163847A1 (en) * | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
| EP1992333A1 (en) | 2007-05-08 | 2008-11-19 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Flurbiprofen and muscle relaxant combinations |
| WO2009092819A1 (en) * | 2008-01-25 | 2009-07-30 | Duo-Ge | Combination of oral medicaments bonded by a wrapping |
| US20090233970A1 (en) | 2008-03-11 | 2009-09-17 | Nickell Robert P | Combined nsaid and acid blocker formulation and method |
| EP1411900B1 (en) | 2001-06-01 | 2010-07-21 | Pozen, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs |
| WO2010084500A1 (en) | 2009-01-22 | 2010-07-29 | Sanofi-Synthelabo (India) Ltd. | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative |
| WO2010120253A1 (en) * | 2009-04-17 | 2010-10-21 | Mustafa Nevzat Ilac Sanayii A.S. | Thiocolchicoside and non-steroidal anti-inflammatory drug combinations |
-
2012
- 2012-03-21 WO PCT/TR2012/000053 patent/WO2012173581A1/en active Application Filing
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725134A1 (en) * | 1994-10-04 | 1996-04-05 | Lederle Lab | Pharmaceutical compsn. of ibuprofen and thiocolchicoside |
| FR2725134B1 (en) | 1994-10-04 | 1996-12-20 | Lederle Lab | NEW PHARMACEUTICAL ASSOCIATION BASED ON IBUPROFEN AND THIOCOLCHICOSIDE |
| FR2735369A1 (en) * | 1995-06-13 | 1996-12-20 | Synthelabo | PHARMACEUTICAL COMPOSITIONS BASED ON SODIUM SALT OF DICLOFENAC AND THIOCOLCHICOSIDE |
| EP0837684B1 (en) | 1995-06-13 | 2002-04-17 | Sanofi-Synthelabo | Pharmaceutical compositions containing a diclofenac salt and thiocolchicoside |
| EP1411900B1 (en) | 2001-06-01 | 2010-07-21 | Pozen, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs |
| US20050163847A1 (en) * | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
| US20070237820A1 (en) | 2004-01-21 | 2007-10-11 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug |
| EP1992333A1 (en) | 2007-05-08 | 2008-11-19 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Flurbiprofen and muscle relaxant combinations |
| WO2009092819A1 (en) * | 2008-01-25 | 2009-07-30 | Duo-Ge | Combination of oral medicaments bonded by a wrapping |
| US20090233970A1 (en) | 2008-03-11 | 2009-09-17 | Nickell Robert P | Combined nsaid and acid blocker formulation and method |
| WO2010084500A1 (en) | 2009-01-22 | 2010-07-29 | Sanofi-Synthelabo (India) Ltd. | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative |
| WO2010120253A1 (en) * | 2009-04-17 | 2010-10-21 | Mustafa Nevzat Ilac Sanayii A.S. | Thiocolchicoside and non-steroidal anti-inflammatory drug combinations |
Non-Patent Citations (2)
| Title |
|---|
| FILALI K ET AL: "The case of a chronic low back pain treatment", ACTUALITES PHARMACEUTIQUES 2002 FR, no. 413, 2002, pages 37 - 40, XP009163705, ISSN: 0515-3700 * |
| SABAT6, E.: "Adherence to Long-Term Therapies: Evidence for Action", WORLD HEALTH ORGANIZATION. GENEVA, 2003, pages 212 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015163832A1 (en) | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
| WO2016001133A1 (en) * | 2014-06-30 | 2016-01-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and gamma-aminobutiric acid receptor agonist combinations |
| US20170151177A1 (en) * | 2014-06-30 | 2017-06-01 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Loxoprofen and gamma-aminobutiric acid receptor agonist combinations |
| WO2016046189A1 (en) * | 2014-09-24 | 2016-03-31 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Loxoprofen and antispastic drug combinations |
| WO2018004498A1 (en) * | 2016-06-30 | 2018-01-04 | Imuneks Farma Ilac San. Ve Tic. A.S. | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation |
| WO2019098983A1 (en) * | 2017-11-16 | 2019-05-23 | Pisak Mehmet Nevzat | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation |
| WO2019135725A1 (en) * | 2018-01-03 | 2019-07-11 | Pisak Mehmet Nevzat | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation |
| WO2019203759A3 (en) * | 2018-01-03 | 2020-01-23 | Pisak Mehmet Nevzat | Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation. |
| WO2020018048A3 (en) * | 2018-05-28 | 2020-07-16 | Pisak Mehmet Nevzat | An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate |
| CN114699380A (en) * | 2021-12-27 | 2022-07-05 | 南京联智医药科技有限公司 | Etodolac tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012173581A4 (en) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012173581A1 (en) | Thiocolchicoside, etodolac and famotidine combinations | |
| CA2690956C (en) | Combination tablet with chewable outer layer | |
| US8404275B2 (en) | Combination tablet with chewable outer layer | |
| EP1411900B1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | |
| WO2012144964A1 (en) | Thiocolchicoside, diclofenac and lansoprazole combinations | |
| JP2011057714A (en) | Gastric acid secretion inhibiting composition | |
| WO2007145991A2 (en) | Anti-inflammatory and analgesic compositions and related methods | |
| EP1330238A1 (en) | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor | |
| BRPI0708640A2 (en) | pharmaceutical composition, and methods for treating a migraine headache patient, treating a pain patient, and treating a migraine patient | |
| KR20040020056A (en) | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough | |
| US20080085314A1 (en) | Solid oral formulations for combination therapy | |
| US7303761B2 (en) | Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin | |
| EP2241310A2 (en) | Modified release formulations of emoxypine | |
| JP2019508464A (en) | Combined preparation containing clopidogrel and aspirin | |
| US20100009005A1 (en) | Novel acetysalicylic acid formulations | |
| KR20190092805A (en) | Pharmaceutical composition comprising Acetylsalicylic acid and Lansoprazole | |
| US20220008441A1 (en) | Compositions and methods for treating multiple sclerosis | |
| JP2017214341A (en) | Oral pharmaceutical formulation | |
| WO2018004498A1 (en) | Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation | |
| JPWO2002066030A1 (en) | Pharmaceutical composition comprising diclofenac and ornoprostil | |
| EP2848261B1 (en) | Pharmaceutical formulations comprising a muscle relaxant and an analgesic combination | |
| WO2019135725A1 (en) | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation | |
| CA2624513A1 (en) | Combination | |
| WO2019098983A1 (en) | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation | |
| WO2018231175A2 (en) | Non-steroidal anti-inflammatory drugs and h2 receptor antagonist combinations for treatment of pain and inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12762419 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013/10814 Country of ref document: TR |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12762419 Country of ref document: EP Kind code of ref document: A1 |